OptionsHouse

Options Trading News

November 27, 2012  Tue 7:23 AM CT

ACAD: SEE CHART GET CHAIN FIND STRATEGIES

Primary and Secondary Endpoints Are Met

Acadia Phaemaceuticals announced successful top-line results for the Phase III trial of its Pimavanserin drug for patients with Parkinson’s disease psychosis. The compound met the primary endpoint by demonstrating highly significant antipsychotic efficacy using a nine-item scale. It also met a secondary endpoint for motoric tolerability. ACAD is up 160 percent before the bell on my tradeMONSTER platform!

Ralcorp Accepts ConAgra Takeover Offer

Ralcorp agreed to be purchased by ConAgra for $90 a share in cash. That's a nice premium for RAH, which closed at $70.23 yesterday, and the stock is up almost 27 percent in early trading.

Las Vegas Sands Rallies on Special Dividend

Las Vegas Sands announced that its board approved a special dividend of $2.75 a share in cash. LVS climbs more than 4 percent in the premarket.

Share this article with your friends


Related Stories

ACAD

Limited upside seen for Acadia Pharma

June 17, 2016

The biopharmaceutical company has seen its share price double in recent months, but one trader is betting that further gains will be limited.

OptionsHouse

Premium Services

Education & Strategy

The Movement of Delta

In our last column, we spoke about delta. You might remember that we discussed what delta was and what factors affected or changed delta. As you recall, we stated that three factors will have an effect on delta. They were movements of time, volatility, and underlying price. Today, we want to take a further look into the change of delta, this time focusing on change due to the movement in the underlying price. 

View more education articles »